Steatohepatitis/Metabolic Liver Disease News

Treatment with Egrifta demonstrated a greater reduction in hepatic fat fraction compared with placebo among patients with nonalcoholic fatty liver disease and HIV, according to study results.

Changes in liver fat can predict changes in steatosis but not other liver histological parameters like improvements in nonalcoholic fatty liver disease activity score or resolution of nonalcoholic steatohepatitis without worsening of fibrosis, according to data published in Journal of Hepatology.

Researchers found that while consumption of red and processed meat, poultry, and cholesterol correlated with nonalcoholic fatty liver disease, dietary fiber intake may reduce the risk for fatty liver and related advanced liver disease, according to data from a multiethnic cohort study.

Investigators have completed trial enrollment for two novel compositions of endogenous metabolic modulators under evaluation as interventions to address dysregulated metabolism in patients with nonalcoholic fatty liver disease, according to a press release from Axcella.

NGM Bio announced positive interim results from ongoing study of aldafermin, an engineered version of human fibroblast growth factor 19 that demonstrated reductions in liver fat among patients with nonalcoholic steatohepatitis, according to a press release.

Results from the EVIDENCES IV trial showed that saroglitazar magnesium achieved its primary endpoint of reduced alanine aminotransferase in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, according to a press release from Zydus Calida.

Dual-photon microscopy automated quantification of fibrosis-related parameters provided accurate assessments of fibrosis in patients with nonalcoholic fatty liver disease, according to data published in Gut.

Enanta Pharmaceuticals announced positive results in alanine aminotransferase and liver fat content reduction from its current trial of EDP-305, a small molecule farnesoid X receptor under investigation for the treatment of nonalcoholic steatohepatitis, according to a press release.

Galmed Pharmaceuticals announced the initiation of a late-stage clinical trial to evaluate Aramchol for the treatment of nonalcoholic steatohepatitis with fibrosis, according to a press release.

Adults with type 1 diabetes assigned to a mealtime, liver-targeted insulin using hepatocyte-directed vesicle technology for 6 months experienced a similar reduction in HbA1c when compared with similar adults assigned to insulin lispro, according to findings published in Diabetes Care.